SCM-02-138

N/A

Report date: 2025/01/26 17:03:22
NME

Base Information

Drug NameSCM-02-138
Drug Alias NameMALT1 inhibitor (Janssen Pharmaceutica/Weill Cornell Medicine/Dana Farber Cancer Institute/Boston Childrens Hospital)SCM-02-138
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMetastasis Associated Lung Adenocarcinoma Transcript 1 inhibitors
TargetsMetastasis Associated Lung Adenocarcinoma Transcript 1
Therapy Area/IndicationsLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJanssen Pharmaceutica NV
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteThe Children's Hospital CorpJanssen Pharmaceutica NV +[4] 
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A